Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer

Conditions:   Head and Neck Cancer;   Human Papilloma Virus
Interventions:   Drug: MEDI0457;   Device: CELLECTRA®5P device (CELLECTRA 2000);   Drug: Durvalumab
Sponsor:   MedImmune LLC
Not yet recruiting - verified May 2017

http://ift.tt/2qOyUyT